Leverage Innovation

At the Molecular Medicine Tri Conference in San Francisco, last week leaders from Pfizer, Johnson and Johnson, Roche and others focused on the need for external partnerships, open innovation and standards.  Chris Waller, Senior Director, Pre Competitive Collaborations, Pfizer, outlined the Pistoia Project focus on pre-competitive partner standards, open innovation amongst its members and individual […]

[Read more →]

On October 1st, at the J. Gladstone Institute on the UCSF Mission Bay campus, a robust conference of scientists from local universities, government, biotech and pharma companies met to focus on collaboration for advancing research.
Speakers from a diverse set of research support areas presented insightful presentations about how to successfully build cross discipline research communities […]

[Read more →]

Web 3.0 is emerging, as a new generation of target handhelds are widely available. Now, there is wide distribution of a thin client (over 37 million Apple iPods, and iPhones) on handheld devices that are truly programmable and interactive, which are the target of a huge number of diverse personal applications services. Local researchers have jumped […]

[Read more →]

As we have discussed in this blog space, acceleration of drug discovery and research has become an overriding corporate operating objective for pharma/biotech firms.  Drugs have become more specialized and complex, requiring new processes of discovery including, Open Innovation (see post of March 2nd) and collaboration to ‘fast forward’ the research and development process.  After reviewing […]

[Read more →]

Based on comments by a diverse set of Pharma/Biotech industry leaders at last weeks’ Molecular Medicine Tri Conference in San Francisco, there is an emerging interest in developing consortia or one-on-one partnerships to share information about IT frameworks, systems, networks, best practices, vendor selection criteria, open source software, collaborative discovery services and other tools that […]

[Read more →]

In reviewing the remarkable rise of Barack Obama to the Presidency, several aspects of his grass roots movement and consensus building efforts standout that we can learn from.  Here are a few attributes of success in driving complex innovation projects: 

Common Interests – he focused his program, staff, website, and initiatives quite often on common interests […]

[Read more →]

The Healthcare Innovation Challenge:  How to increase innovation productivity and reduce the 7+ years on average to launch a new drug? According to figures released by the FDA, CDER, PhRMA and Price Waterhouse Coopers, for 2007, drug industry spending has actually doubled on R & D with the number of drugs actually delivered to patients […]

[Read more →]